Search Results
You are looking at 1 - 2 of 2 items for
- Author: Mohammad Bohlooly-Y x
- Refine by access: All content x
Search for other papers by Marion Walser in
Google Scholar
PubMed
Laboratory of Experimental Endocrinology, Endocrinology, Department of Clinical Chemistry and Transfusion Medicine, Institute of Neuroscience and Physiology, Department of Primary Health Care, AstraZeneca Research and Development, Clinical Neurochemistry Laboratory, InnoExt AB, Department of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gröna Stråket 8, SE-41345 Göteborg, Sweden
Search for other papers by Maria Teresa Samà in
Google Scholar
PubMed
Search for other papers by Ruth Wickelgren in
Google Scholar
PubMed
Laboratory of Experimental Endocrinology, Endocrinology, Department of Clinical Chemistry and Transfusion Medicine, Institute of Neuroscience and Physiology, Department of Primary Health Care, AstraZeneca Research and Development, Clinical Neurochemistry Laboratory, InnoExt AB, Department of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gröna Stråket 8, SE-41345 Göteborg, Sweden
Search for other papers by Maria Åberg in
Google Scholar
PubMed
Search for other papers by Mohammad Bohlooly-Y in
Google Scholar
PubMed
Search for other papers by Bob Olsson in
Google Scholar
PubMed
Search for other papers by Jan Törnell in
Google Scholar
PubMed
Search for other papers by Jörgen Isgaard in
Google Scholar
PubMed
Laboratory of Experimental Endocrinology, Endocrinology, Department of Clinical Chemistry and Transfusion Medicine, Institute of Neuroscience and Physiology, Department of Primary Health Care, AstraZeneca Research and Development, Clinical Neurochemistry Laboratory, InnoExt AB, Department of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gröna Stråket 8, SE-41345 Göteborg, Sweden
Search for other papers by N David Åberg in
Google Scholar
PubMed
GH therapy improves hippocampal functions mainly via circulating IGF1. However, the roles of local GH and IGF1 expression are not well understood. We investigated whether transgenic (TG) overexpression in the adult brain of bovine GH (bGH) under the control of the glial fibrillary acidic protein (GFAP) promoter affected cellular proliferation and the expression of transcripts known to be induced by systemic GH in the hippocampus. Cellular proliferation was examined by 5-bromo-2′-deoxyuridine immunohistochemistry. Quantitative PCR and western blots were performed. Although robustly expressed, bGH-Tg did not increase either cell proliferation or survival. However, bGH-Tg modestly increased Igf1 and Gfap mRNAs, whereas other GH-associated transcripts were unaffected, i.e. the GH receptor (Ghr), IGF1 receptor (Igf1r), 2′,3′-cyclic nucleotide 3′-phosphodiesterase (Cnp), ionotropic glutamate receptor 2a (Nr2a (Grin2a)), opioid receptor delta (Dor), synapse-associated protein 90/postsynaptic density-95-associated protein (Sapap2 (Dlgap2)), haemoglobin beta (Hbb) and glutamine synthetase (Gs (Glul)). However, IGF1R was correlated with the expression of Dor, Nr2a, Sapap2, Gs and Gfap. In summary, although local bGH expression was robust, it activated local IGF1 very modestly, which is probably the reason for the low response of previous GH-associated response parameters. This would, in turn, indicate that hippocampal GH is less important than endocrine GH. However, as most transcripts were correlated with the expression of IGF1R, there is still a possibility for endogenous circulating or local GH to act via IGF1R signalling. Possible reasons for the relative bio-inactivity of bGH include the bell-shaped dose–response curve and cell-specific expression of bGH.
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Dania Russo in
Google Scholar
PubMed
Search for other papers by Francesco Raggi in
Google Scholar
PubMed
Search for other papers by Mohammad Bohlooly-Y in
Google Scholar
PubMed
Search for other papers by Jan Tornell in
Google Scholar
PubMed
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Search for other papers by Martina Lombardi in
Google Scholar
PubMed
Search for other papers by Claudio Urbani in
Google Scholar
PubMed
Search for other papers by Luca Manetti in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Enio Martino in
Google Scholar
PubMed
Apoptosis may occur through the mitochondrial (intrinsic) pathway and activation of death receptors (extrinsic pathway). Young acromegalic mice have reduced cardiac apoptosis whereas elder animals have increased cardiac apoptosis. Multiple intrinsic apoptotic pathways have been shown to be modulated by GH and other stimuli in the heart of acromegalic mice. However, the role of the extrinsic apoptotic pathways in acromegalic hearts is currently unknown. In young (3-month-old) acromegalic mice, expression of proteins of the extrinsic apoptotic pathway did not differ from that of wild-type animals, suggesting that this mechanism did not participate in the lower cardiac apoptosis levels observed at this age. On the contrary, the extrinsic pathway was active in elder (9-month-old) animals (as shown by increased expression of TRAIL, FADD, TRADD and increased activation of death inducing signaling complex) leading to increased levels of active caspase 8. It is worth noting that changes of some pro-apoptotic proteins were induced by GH, which seemed to have, in this context, pro-apoptotic effects. The extrinsic pathway influenced the intrinsic pathway by modulating t-Bid, the cellular levels of which were reduced in young and increased in elder animals. However, in young animals this effect was due to reduced levels of Bid regulated by the extrinsic pathway, whereas in elder animals the increased levels of t-Bid were due to the increased levels of active caspase 8. In conclusion, the extrinsic pathway participates in the cardiac pro-apoptotic phenotype of elder acromegalic animals either directly, enhancing caspase 8 levels or indirectly, increasing t-Bid levels and conveying death signals to the intrinsic pathway.